Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aldeyra Therapeu (ALDX)

Aldeyra Therapeu (ALDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 493,580
  • Shares Outstanding, K 57,864
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,550 K
  • 60-Month Beta 1.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.27
Trade ALDX with:

Options Overview

Details
  • Implied Volatility 93.06%
  • Historical Volatility 42.69%
  • IV Percentile 36%
  • IV Rank 25.12%
  • IV High 195.72% on 10/09/20
  • IV Low 58.63% on 07/21/21
  • Put/Call Vol Ratio 0.41
  • Today's Volume 369
  • Volume Avg (30-Day) 980
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 20,500
  • Open Int (30-Day) 16,659

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.29
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.33
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -26.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.02 +6.86%
on 08/20/21
9.81 -12.64%
on 09/02/21
-0.18 (-2.06%)
since 08/17/21
3-Month
8.02 +6.86%
on 08/20/21
12.23 -29.93%
on 06/18/21
-3.58 (-29.47%)
since 06/17/21
52-Week
6.21 +38.00%
on 10/29/20
15.95 -46.27%
on 04/27/21
+1.46 (+20.53%)
since 09/17/20

Most Recent Stories

More News
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with...

ALDX : 8.57 (+0.47%)
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the...

ALDX : 8.57 (+0.47%)
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection)...

ALDX : 8.57 (+0.47%)
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the BTIG...

ALDX : 8.57 (+0.47%)
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent...

ALDX : 8.57 (+0.47%)
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer

The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.

CORT : 20.51 (-0.58%)
CANF : 1.7400 (unch)
ALDX : 8.57 (+0.47%)
FHTX : 13.23 (+1.22%)
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company for ADX-2191 (methotrexate for intravitreal...

ALDX : 8.57 (+0.47%)
Aldeyra Therapeutics Joins the Russell 2000(R) and Russell 3000(R) Indexes

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that the company was added...

ALDX : 8.57 (+0.47%)
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the Jefferies...

ALDX : 8.57 (+0.47%)
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated...

ALDX : 8.57 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 9.12
2nd Resistance Point 8.86
1st Resistance Point 8.71
Last Price 8.57
1st Support Level 8.30
2nd Support Level 8.04
3rd Support Level 7.89

See More

52-Week High 15.95
Fibonacci 61.8% 12.23
Fibonacci 50% 11.08
Fibonacci 38.2% 9.93
Last Price 8.57
52-Week Low 6.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar